Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers December 5, 2016
Pharmacy Choice - News - U.S. Pharmaceutical Industry - December 5, 2016

Pharmacy News

 U.S. Pharmaceutical Industry
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

12/5/16 - Abbott Laboratories Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities (Nov. 18, 2016)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Abbott Laboratories was posted on November 18, 2016. The SEC file number is 0001179110-16-031866.. A U.S. Securities and Exchange Commission filing i
12/5/16 - Abbott Laboratories Files SEC Form 424B5, Prospectus [Rule 424(B)(5)] (Nov. 17, 2016)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Abbott Laboratories was posted on November 17, 2016. The SEC file number is 0001047469-16-016782.. A U.S. Securities and Exchange Commission filing i
12/5/16 - Abbott Laboratories Files SEC Form 424B5, Prospectus [Rule 424(B)(5)] (Nov. 21, 2016)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Abbott Laboratories was posted on November 18, 2016. The SEC file number is 0001047469-16-016848.. A U.S. Securities and Exchange Commission filing i
12/5/16 - Abbott Laboratories Files SEC Form 8-K, Current Report (Nov. 17, 2016)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Abbott Laboratories was posted on November 17, 2016. The SEC file number is 0001104659-16-157712.. A U.S. Securities and Exchange Commission filing i
12/5/16 - Abbott Laboratories Files SEC Form FWP, Filing Under Securities Act Rules 163/433 of Free Writing Prospectuses (Nov. 18, 2016)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Abbott Laboratories was posted on November 17, 2016. The SEC file number is 0001104659-16-157893.. A U.S. Securities and Exchange Commission filing i
12/5/16 - Ability to Delay Type 2 Diabetes Disease Progression by Preserving Beta Cell Mass Observed in New Imeglimin Data
POXEL SA, a biopharmaceutical company focused on the development of innovative treatments for type 2 diabetes, today announced the presentation of preclinical data supporting Imeglimin s drug profile as a novel diabetes therapy. We are continuing to add further differentiating data to Imeglimin s exciting clinical results as we learn more
12/5/16 - Acceleron and Celgene Announce Preliminary Results from an Investigator Initiated Phase 2 Study of Sotatercept in Myelofibrosis at the 58th Annual Meeting of the American Society of Hematology
CAMBRIDGE, Mass.& SUMMIT, N.J. Acceleron Pharma Inc. and Celgene Corporation, today announced preliminary results from an ongoing investigator initiated Phase 2 study with investigational drug sotatercept in patients with myelofibrosis at the 58 th Annual Meeting of the American Society of Hematology in San Diego, California. Sotatercept is bei
12/5/16 - Acceleron Pharma Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities (Nov. 18, 2016)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Acceleron Pharma Inc. was posted on November 18, 2016. The SEC file number is 0001209191-16-151236.. A U.S. Securities and Exchange Commission filing
12/5/16 - Adamas Pharmaceuticals Inc. Files SEC Form EFFECT, Notice of Effectiveness (Nov. 22, 2016)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Adamas Pharmaceuticals Inc. was posted on November 22, 2016. The SEC file number is. A U.S. Securities and Exchange Commission filing is a formal doc
12/5/16 - ADIENNE Pharma & Biotech presenting at 58th Annual ASH Meeting with session on Clinical Allogeneic Transplantation
ADIENNE Pharma& Biotech presenting at 58th Annual ASH Meeting with session on Clinical Allogeneic Transplantation. Lugano, December 5, 2016; ADIENNE Pharma& Biotech SA, an integrated biopharmaceutical group of companies based in Switzerland, announced that leading experts in the field of onco-hematology and bone marrow transplantation today have...
12/5/16 - Aduro Biotech Announces Anti-CD27 Agonist, an Investigational Anti-Cancer Immunotherapy, Advancing in Collaboration with MSD
Aduro Biotech, Inc., a biopharmaceutical company with three distinct immunotherapy technologies, announced today that an anti-CD27 antibody developed by Aduro Biotech Europe and derived from its proprietary B-select technology has been selected to be advanced into clinical development by Merck& Co., Inc., Kenilworth, NJ, USA, through a subsidiary
12/5/16 - Aegerion Pharmaceuticals, a Subsidiary ofNovelionTherapeutics, Enters into Agreement in Principle to Settle Class Action Shareholder Lawsuit
Novelion Therapeutics Inc., a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced that on December 3, 2016, Aegerion Pharmaceuticals, an indirect, wholly-owned subsidiary of Novelion, entered into an agreement in principle to settle all claims in the class action shareho
12/5/16 - Agios Pharmaceuticals Inc. Files SEC Form 8-K, Current Report (Nov. 18, 2016)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Agios Pharmaceuticals Inc. was posted on November 18, 2016. The SEC file number is 0001193125-16-771481.. A U.S. Securities and Exchange Commission f
12/5/16 - AGTC to Present at Upcoming Conferences
Applied Genetic Technologies Corporation, a biotechnology company conducting human clinical trials of adeno-associated virus- based gene therapies for the treatment of rare diseases, today announced its participation in upcoming conferences.. Genetic Rx Boston, Mass. AGTC President& CEO Sue Washer will be moderating a panel discussion entitled
12/5/16 - Alimera Sciences Inc. Files SEC Form SC 13G, Statement of Acquisition of Beneficial Ownership By Individuals (Nov. 17, 2016)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Alimera Sciences Inc. was posted on November 17, 2016. The SEC file number is 0000935836-16-001192.. A U.S. Securities and Exchange Commission filing
12/5/16 - Allergan PLC Investors With Losses In Excess of $1,000,000 Are Reminded to Contact the Rosen Law Firm Regarding the Important Deadline in Class...
By a News Reporter-Staff News Editor at Pharma Business Week Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Allergan plc and/or Actavis plc between February 25, 2014 and November 3, 2016, both dates inclusive of the important January 3, 2017 lead plaintiff deadline in the class action filed by the firm.
12/5/16 - Allergan's Trademark Application for "SERISCAFFOLD" Filed
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a trademark application has been made for "SERISCAFFOLD" by Susan J. Hinchey, representing Allergan. The owner/registrar information for this application is: Susan J. Hinchey, Allergan, 2525 Dupont Dri
12/5/16 - ALNY In Motion, Shire Finds New Use For Old Drug, TFX Snaps Up VASC
SAINT HELIER- Alnylam Pharmaceuticals Inc., on Sunday, reported positive interim clinical results of its investigational RNAi therapeutic Fitusiran from an ongoing phase II open label extension study in patients with Hemophilia A or B without inhibitors. Acceleron Pharma Inc. and Celgene Corp., on Sunday, announced encouraging preliminary results f
12/5/16 - Alnylam Presents Updated Results from Phase 1/2 Study of ALN-CC5 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, today presented new results from Part C of its Phase 1/ 2 clinical trial with ALN-CC5, a subcutaneously administered investigational RNAi therapeutic targeting complement component 5 for the treatment of complement-mediated diseases, in a poster presentation at the 58th Annual...
12/5/16 - Alzheon to Present New Clinical Data and Analyses for ALZ-801, an Amyloid-Targeted Drug Candidate, and its Active Molecule Tramiprosate at the 9th...
Alzheon to Present New Clinical Data and Analyses for ALZ-801, an Amyloid-Targeted Drug Candidate, and its Active Molecule Tramiprosate at the 9th Clinical Trials on Alzheimer's Disease Congress. By a News Reporter-Staff News Editor at Clinical Trials Week Alzheon, Inc., a clinical-stage biopharmaceutical company focused on developing new medicin
12/5/16 - Ampio Pharmaceuticals, Inc. Files SEC Form DEF 14A, Other Definitive Proxy Statements (Nov. 22, 2016)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Ampio Pharmaceuticals, Inc. was posted on November 22, 2016. The SEC file number is 0001144204-16-135775.. A U.S. Securities and Exchange Commission
12/5/16 - An Application for the Trademark "SKINMEDICA <>" Has Been Filed by Allergan
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a trademark application has been made for " SKINMEDICA <>" by Susan J. Hinchey, representing Allergan. This application was made available to the public on November 20, 2016. The mark consists of the l
12/5/16 - Antibacterial Drug Resistance: Market Landscape, Challenges and Upcoming Opportunities, 2016-2026 - Research and Markets
Research and Markets has announced the addition of the "Antibacterial Drug Resistance: Market Landscape, Challenges and Upcoming Opportunities, 2016-2026" report to their offering. The "Antibacterial Drug Resistance: Market Landscape, Challenges and Upcoming Opportunities, 2016-2026" report provides an extensive study of the current landscape and t
12/5/16 - Ariad Pharmaceuticals Inc. Files SEC Form 8-K, Current Report (Nov. 18, 2016)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Ariad Pharmaceuticals Inc. was posted on November 18, 2016. The SEC file number is 0001157523-16-007411.. A U.S. Securities and Exchange Commission f
12/5/16 - ARIAD Presents Updated Brigatinib Data with 18.4 Months Median Intracranial Progression Free Survival (PFS) in ALK+ NSCLC Patients with CNS Metastases at the World Conference on Lung Cancer
~Investor and analyst call to be held on Wednesday, December 7 at 4:00 p.m. Central European Time. CAMBRIDGE, Mass.& VIENNA ARIAD Pharmaceuticals, Inc., a rare cancer-focused innovative biotechnology company, today announced clinical data on brigatinib, its investigational anaplastic lymphoma kinase inhibitor, from the ongoing Phase 1/ 2 and pi
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2016 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415